Behrang Saminejad, MD
Neurology · Allentown, PANPI 1932416682
Payments from drug & device makers
Across 912 payments — averaging $715.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$248K
- Neurocrine Biosciences, Inc.$180K
- Kyowa Kirin, Inc.$62K
- AbbVie$53K
- MDD US Operations, LLC$43K
- Acorda Therapeutics, Inc$30K
- plus $37K from 16 others
Across 7 payments — averaging $1778.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$11K
- Medtronic$1K
What the payments were for
- Consulting fees$62,53111%
- Speaking & faculty fees$450,92776%
- Travel & lodging$55,4149%
- Food & beverage$23,9344%
- Education$1,5960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 295 | $247,903 |
| Neurocrine Biosciences, Inc. | 220 | $180,036 |
| Kyowa Kirin, Inc. | 58 | $61,793 |
| AbbVie | 36 | $52,896 |
| MDD US Operations, LLC | 79 | $43,023 |
| Acorda Therapeutics, Inc | 51 | $30,043 |
| Acadia Pharmaceuticals Inc | 7 | $11,910 |
| Adamas Pharmaceuticals, Inc. | 12 | $10,569 |
| Medtronic(2 entities) | 91 | $7,505 |
| Abbott | 19 | $2,521 |
| Amneal Pharmaceuticals LLC | 3 | $1,479 |
| Boston Scientific | 10 | $1,470 |
| AstraZeneca | 1 | $700 |
| Ipsen Biopharmaceuticals, Inc | 3 | $248 |
| Argenx US, Inc. | 9 | $209 |
| Insightec,inc | 2 | $132 |
| Revance Therapeutics, Inc. | 4 | $106 |
| Merz North America, Inc. | 2 | $69 |
| Springworks Therapeutics, Inc. | 3 | $55 |
| Supernus Pharmaceuticals, Inc. | 5 | $53 |
| Merz Pharmaceuticals, LLC | 1 | $16 |
| UCB, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$170,722
- Austedo XR$142,090
- AUSTEDO$101,463
- NOURIANZ$61,537
- INBRIJA$28,758
- GOCOVRI$15,311
- MYOBLOC$4,683
- PERCEPT PC BRAINSENSE$4,373
- ONGENTYS$3,841
- Duopa$3,643
- INFINITY$2,299
- VERCISE$1,037
- ONGENTYS 50MG CAPSULES 30$932
- NUPLAZID$875
- RECLAIM$660
- ACTIVA$640
- DYSPORT$237
- WAVEWRITER ALPHA$197
- UZEDY$113
- QULIPTA$109
How this compares
$652,748 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 96 | $690,072 |
| IngrezzaValbenazine Tosylate | 55 | $336,520 |
| AustedoDeutetrabenazine | 34 | $280,736 |
| InbrijaLevodopa | 25 | $125,695 |
| GocovriAmantadine Hcl | 31 | $119,123 |
| NuplazidPimavanserin Tartrate | 20 | $95,758 |
| RytaryCarbidopa/Levodopa | 55 | $65,714 |
| Tetrabenazine | 17 | $53,581 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 814 | $43,223 |
| CrexontCarbidopa/Levodopa | 22 | $26,352 |
| Rasagiline Mesylate | 82 | $16,063 |
| OngentysOpicapone | 21 | $16,048 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 201 | $12,096 |
| Rivastigmine | 58 | $8,205 |
| Primidone | 188 | $7,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $247,903 | $970,808130 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $180,036 | $352,56876 claims |
| Acorda Therapeutics, IncInbrija | $30,043 | $125,69525 claims |
| MDD US Operations, LLCGocovri | $43,023 | $119,12331 claims |
| Acadia Pharmaceuticals IncNuplazid | $11,910 | $95,75820 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $1,479 | $92,06677 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Allentown
- Gary ClauserAllentown$518K
- Christopher WohlbergAllentown$358K
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.